SAN FRANCISCO -- Circulating tumor DNA (ctDNA) measurements showed promise for identifying patients with early colorectal ...

A retrospective analysis assessed the prognostic value of preoperative ctDNA testing among patients who underwent radical cystectomy for bladder cancer.

New data from two large studies presented at the 2025 ASCO Gastrointestinal Cancers Symposium (GICS) 2025 provide evidence of the clinical utility of circulating tumor DNA (ctDNA) testing in ...

Serial circulating tumor DNA (ctDNA) testing showed limited clinical benefit in colorectal cancer (CRC) surveillance when frequent imaging is used. The study's retrospective design and small sample ...

Please provide your email address to receive an email when new articles are posted on . Approximately 25% of patients had ctDNA- or imaging-confirmed recurrence. More than 30% had evidence of ...

The 2026 ASCO annual meeting featured an oral abstract kidney cancer session and a presentation by Dr. Toni Choueiri discussing a ctDNA analysis in participants with renal cell carcinoma (RCC) treated ...

India, March 23 -- Advances in cancer research are improving how doctors diagnose and monitor diseases. One emerging tool is circulating tumor DNA, often called ctDNA, which is gaining attention in ...

For years, breast cancer treatment has been guided by genetic alterations found in tumor tissue, typically through invasive biopsies. However, the dynamic nature of cancer and limitations in tissue ...

Dr. W. Fraser Symmans explains how ctDNA is replacing CTCs to monitor breast cancer, detect mutations and track minimal residual disease At the CURE Educated Patient Breast Cancer Summit, held during ...